Form 4: Lexeo Therapeutics Director Brenda Cooperstone Receives Stock Option Grant

Lexeo Therapeutics, Inc. Director Brenda Cooperstone was granted 25,000 stock options with an exercise price of $4.18, vesting on the earlier of June 26, 2026, or the next annual stockholders meeting.

Summary

• Brenda Cooperstone, a Director of Lexeo Therapeutics, Inc. (LXEO), was granted 25,000 stock options.
• The options have an exercise price of $4.18 per share.
• The grant date for these options was June 26, 2025.
• The options will vest 100% on the earlier of June 26, 2026, or the date of the Issuer's next annual stockholders meeting, contingent on her continuous service.
• The options expire on June 25, 2035.
• Following this transaction, Brenda Cooperstone beneficially owns 25,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments. It's a standard corporate governance action.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• Potential for future share dilution if the options are exercised, increasing the number of outstanding shares.

Future Outlook

NA

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as across publicly traded companies, to attract and retain qualified board members and align their incentives with company performance. This practice is standard for compensating non-employee directors.

Comparison to Industry Standards

• The grant of 25,000 stock options to a director is within the typical range for non-employee director compensation in the biotech sector, though specific values vary widely based on company stage, market capitalization, and board responsibilities.
• The exercise price of $4.18, which is likely the closing price on the grant date, is standard for incentive stock options.
• A vesting period of approximately one year (until June 26, 2026, or the next annual meeting) is a common vesting schedule for annual director equity grants, similar to practices at companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, which often involve annual equity grants that vest over one year or upon the next annual meeting.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making. However, future exercise could lead to minor dilution.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The stock options will vest on the earlier of June 26, 2026, or the date of Lexeo Therapeutics' next annual stockholders meeting, subject to Brenda Cooperstone's continuous service.

Key Dates

Recommendation

Keywords

Lexeo Therapeutics, LXEO, Form 4, stock options, director compensation, equity grant, insider transaction, Brenda Cooperstone